Cambridge Investment Research Advisors, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 79,583 shares of RXRX stock, worth $519,676. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,583
Previous 76,968
3.4%
Holding current value
$519,676
Previous $577,000
9.19%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RXRX
# of Institutions
289Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$214 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$165 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$159 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$113 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$100 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.18B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...